Innovation is about the application of new ideas, discoveries and inventions. The innovative and entrepreneurial spirit of the members of the University of Cambridge is enshrined in the University’s mission statement to contribute to society through the pursuit of education, learning and research at the highest international levels of excellence. The foundation for innovation is the steady supply of excellent ideas, of which there is an abundance at Cambridge. Ingenuity and creativity, alongside the fundamental research which underpins these ideas and combined with the constant exchange of ideas between academics and companies, governments and NGOs has been the recipe for this success.
Various mechanisms are in place to help our academics nurture future innovation. As well as dedicated departmental support structures, Cambridge Enterprise provides technology transfer, consultancy services and seed fund opportunities, and the Centre for Entrepreneurial Learning (CfEL) within the Judge Business School provides networking opportunities with peers. In addition, Cambridge-based initiatives physically embedded within the University such as ideaSpace provide hubs for entrepreneurs to develop ideas.
A new drug based on decades of research at the University of Cambridge has today been approved by the National Institute for Health and Care Excellence (NICE) for use in people with relapsing-remitting multiple sclerosis. Clinical trials have shown that Alemtuzumab, marketed under the name Lemtrada, reduces disease activity, limits the accumulation of further disability over time and may even allow some existing damage to recover.